A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Clinical trial NCT04847102 · UNKNOWN
Trial details
- NCT number
- NCT04847102
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-22
- Primary completion
- 2021-11-30
- Enrollment
- 28000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.